市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Belite Bio, Inc | 看跌 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | 1.38 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 54.27% |
| 机构持股比例 | 1.10% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 100.00 (HC Wainwright & Co., 63.64%) | 购买 |
| 中 | 90.00 (47.28%) | |
| 低 | 80.00 (Benchmark, 30.91%) | 购买 |
| 平均值 | 90.00 (47.28%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 66.80 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Benchmark | 26 Mar 2025 | 80.00 (30.91%) | 购买 | 65.21 |
| HC Wainwright & Co. | 18 Mar 2025 | 100.00 (63.64%) | 购买 | 68.38 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合